These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28770449)

  • 1. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
    Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
    Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
    Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
    Khan QJ; Reddy PS; Kimler BF; Sharma P; Baxa SE; O'Dea AP; Klemp JR; Fabian CJ
    Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
    Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole.
    Arul Vijaya Vani S; Ananthanarayanan PH; Kadambari D; Harichandrakumar KT; Niranjjan R; Nandeesha H
    Clin Chim Acta; 2016 Aug; 459():53-56. PubMed ID: 27221206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
    Hershman DL; Unger JM; Crew KD; Awad D; Dakhil SR; Gralow J; Greenlee H; Lew DL; Minasian LM; Till C; Wade JL; Meyskens FL; Moinpour CM
    J Clin Oncol; 2015 Jun; 33(17):1910-7. PubMed ID: 25940724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
    Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
    Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: A randomized, controlled clinical trial.
    Peng N; Yu M; Yang G; Fu Q; Xu Y; Yu J; Liu Q; Li C; Xu W; Zhang Y; Ma C; Yang L; Yu R; Wang X
    Breast; 2018 Feb; 37():18-27. PubMed ID: 29059538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
    Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
    Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
    Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Harris DR; Price G; Baker A; Meyer WA; Wilson CM; Hazra R; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2018 Jan; 66(2):220-228. PubMed ID: 29020329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
    Niravath P; Hilsenbeck SG; Wang T; Jiralerspong S; Nangia J; Pavlick A; Ademuyiwa F; Frith A; Ma C; Park H; Rigden C; Suresh R; Ellis M; Kent Osborne C; Rimawi MF
    Breast Cancer Res Treat; 2019 Sep; 177(2):427-435. PubMed ID: 31218477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
    Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
    Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
    J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
    Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
    Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
    Martínez N; Herrera M; Frías L; Provencio M; Pérez-Carrión R; Díaz V; Morse M; Crespo MC
    Clin Transl Oncol; 2019 Apr; 21(4):489-498. PubMed ID: 30293230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double-blind placebo-controlled study adding high dose vitamin D to analgesic regimens in patients with musculoskeletal pain.
    Gendelman O; Itzhaki D; Makarov S; Bennun M; Amital H
    Lupus; 2015 Apr; 24(4-5):483-9. PubMed ID: 25801891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
    Singh S; Cuzick J; Mesher D; Richmond B; Howell A
    Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.